rewrite this title and make it good for SEONeurocrine Biosciences, Inc. (NBIX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Marc GoodmanLeerink Partners LLC, Research Division

Thanks for joining us. I’m Marc Goodman, one of the Biopharma Analyst at Leerink, and it’s great to have Neurocrine here. We have Matt Abernethy, who’s the CFO; and Todd Tushla, who’s the IR guy. Thank you very much for joining us.

Matt, I’ll give you a chance just to make an opening comment, maybe not too long, but just kind of set the stage.

Matthew AbernethyChief Financial Officer

I’ll try to run out the clock if that’s okay. And we’ll pivot a little bit throughout this presentation. How about that, Marc? We will be making forward-looking statements. So we’ll direct you to our latest SEC filings for the related risk factors and uncertainties associated with our company and then also our industry. Now that we have that fun fact behind us. We’re at a great spot, Marc. We had — how long was that dinner last night about 2 hours?

Marc GoodmanLeerink Partners LLC, Research Division

Yes, because they didn’t serve the food very quickly.

Matthew AbernethyChief Financial Officer

Yes. They were still catching the salmon. But to be at a spot where you have 2 approved products at this point is just incredible. You have $2.7 billion to $2.8 billion guide for the year for INGREZZA. INGREZZA has actually been on the market 9 years now. And to be at a place to have double-digit growth still is just quite significant. We recently expanded the sales force. The sales force will be in place starting the beginning of Q2, but was at a national sales